Astonea Labs SME: Check IPO Date, Live Subscription and Key Details
Founded in 2017, Astonea Labs Ltd. specializes in contract manufacturing of pharmaceutical and cosmetic products for both domestic and international clients. The company produces a wide range of medicines including antibiotics, antihistamines, and treatments for conditions like diabetes, heart issues, and gynecological disorders, along with skincare, dental, and haircare products in forms like gels, creams, and serums.
Price Range
₹128.00-135.00
Issue Size
₹37.67 Cr
Lot Size
1,000 shares
IPO Type
BSE SME
GMP
-
Est. Listing Price
₹135
Estimate Profit
-
Retail Portion
-
Key Metrics
Check Live GMPGMPFace Value
₹10
EPS
5.2
P/E Ratio
25.94
RoNW
31.83%
ROE
37.86%
Debt to Equity
2.16
Advertisement
Timeline
IPO Opens
27 May
IPO Closes
29 May
Allotment
30 May
Listing
3 Jun
IPO Timeline & Listing Details
| Event | Date | Details |
|---|---|---|
| IPO Open Date | 27 May 2025 | Subscription starts |
| IPO Close Date | 29 May 2025 | Subscription ends |
| Allotment Date | 30 May 2025 | Allotment |
| Listing Date | 3 June 2025 | Listing |
Investment Categories
| Category | Lots | Amount |
|---|---|---|
Individual | 2 | ₹2,70,000 |
SHNI (Min) | 3 | ₹4,05,000 |
SHNI (Max) | 7 | ₹9,45,000 |
BHNIAbove ₹10,00,000 | 8 | ₹10,80,000 |
IPO Objectives
- Funding of expenses proposed to be incurred towards registration in Bolivia, South America
- Purchase and installation of plant and machineries for ointment production for the purpose of export in accordance with the international standards and protocols, on the 2nd floor of the Existing Premises
- Advertising, marketing and brand building
- Investment in procuring hardware and software
- Funding of working capital requirements
- General corporate purposes.
Strengths
- Robust marketing and distribution network supports both domestic and international operations.
- Seasoned management team with strong expertise in the pharmaceutical and cosmetics industries.
- Expanding and diverse product portfolio across pharma and cosmetic verticals.
- High-quality, innovative offerings provide a competitive advantage in niche segments.
Weaknesses
- Requires significant funding to scale operations at a national level.
- Market share remains limited in several key product segments.
- Highly influenced by market trends and intense industry competition.
- Vulnerable to pricing pressure from established local and global competitors.
Advertisement
Financial Performance
| Period Ended | 31 Dec 2024 | 31 Mar 2024 | 31 Mar 2023 | 31 Mar 2022 |
|---|---|---|---|---|
| Assets (₹ Cr.) | 96.52 | 80.89 | 64.28 | 52.91 |
| Revenue (₹ Cr.) | 69.69 | 80.29 | 67.26 | 30.17 |
| PAT (₹ Cr.) | 4.1 | 3.81 | 0.67 | 0.25 |
| Net Worth (₹ Cr.) | 17.28 | 11.97 | 8.16 | 7.49 |
Peer Comparison
| Company | P/B Ratio | P/E Ratio | RONW (%) | Net Worth (₹ Cr.) |
|---|---|---|---|---|
| Astonea Labs Ltd | 9 | 25.94 | 31.83% | 17.28 |
| Beta Drugs Limited | 11.39 | 49 | 23.19% | 157 |
Subscription Details
Daily Bids Status
| Category | Day 1 | Day 2 | Day 3 |
|---|---|---|---|
| QIB | 0x | 0.11x | 0.7x |
| NII | 0.65x | 2.28x | 5.6x |
| RII | 0.35x | 0.68x | 1.68x |
| Total | 0.22x | 0.64x | 1.78x |
Overall Subscription Statistics
| Category | Shares Offered | Shares Bid | Bid Amount (₹ Cr) |
|---|---|---|---|
| QIB | 13,20,000 | 9,27,000 | 12.51 |
| NII | 3,99,000 | 22,33,000 | 30.15 |
| RII | 9,27,000 | 15,53,000 | 20.97 |
| Total | 26,46,000 | 47,13,000 | 63.63 |
Advertisement
Company Details
- Astonea Labs
- House No. 1358, 1st Floor, Sector-22B, Chandigarh, 160022
- +91 9888302323
- cs@astonea.org
- https://www.astonea.org/
Registrar Details
- Kfin Technologies Limited
- 04067162222, 04079611000
- murali.m@kfintech.com
- https://kosmic.kfintech.com/ipostatus/
Loading comments...